|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUP37 |
Gene summary for NUP37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUP37 | Gene ID | 79023 |
| Gene name | nucleoporin 37 | |
| Gene Alias | MCPH24 | |
| Cytomap | 12q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0006403 | UniProtAcc | Q8NFH4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79023 | NUP37 | LZE4T | Human | Esophagus | ESCC | 2.45e-03 | 1.61e-01 | 0.0811 |
| 79023 | NUP37 | LZE5T | Human | Esophagus | ESCC | 4.78e-02 | 1.41e-01 | 0.0514 |
| 79023 | NUP37 | LZE7T | Human | Esophagus | ESCC | 7.32e-09 | 4.69e-01 | 0.0667 |
| 79023 | NUP37 | LZE8T | Human | Esophagus | ESCC | 9.22e-07 | 2.45e-01 | 0.067 |
| 79023 | NUP37 | LZE20T | Human | Esophagus | ESCC | 2.58e-03 | 9.02e-02 | 0.0662 |
| 79023 | NUP37 | LZE22T | Human | Esophagus | ESCC | 1.46e-04 | 3.63e-01 | 0.068 |
| 79023 | NUP37 | LZE24T | Human | Esophagus | ESCC | 2.27e-11 | 3.45e-01 | 0.0596 |
| 79023 | NUP37 | LZE21T | Human | Esophagus | ESCC | 1.69e-03 | 2.25e-01 | 0.0655 |
| 79023 | NUP37 | LZE6T | Human | Esophagus | ESCC | 8.27e-07 | 4.13e-01 | 0.0845 |
| 79023 | NUP37 | P1T-E | Human | Esophagus | ESCC | 2.90e-03 | 3.80e-01 | 0.0875 |
| 79023 | NUP37 | P2T-E | Human | Esophagus | ESCC | 1.04e-31 | 7.53e-01 | 0.1177 |
| 79023 | NUP37 | P4T-E | Human | Esophagus | ESCC | 4.21e-24 | 7.43e-01 | 0.1323 |
| 79023 | NUP37 | P5T-E | Human | Esophagus | ESCC | 9.81e-32 | 6.75e-01 | 0.1327 |
| 79023 | NUP37 | P8T-E | Human | Esophagus | ESCC | 1.35e-21 | 3.66e-01 | 0.0889 |
| 79023 | NUP37 | P9T-E | Human | Esophagus | ESCC | 6.71e-14 | 2.01e-01 | 0.1131 |
| 79023 | NUP37 | P10T-E | Human | Esophagus | ESCC | 6.99e-20 | 3.21e-01 | 0.116 |
| 79023 | NUP37 | P11T-E | Human | Esophagus | ESCC | 9.47e-09 | 4.14e-01 | 0.1426 |
| 79023 | NUP37 | P12T-E | Human | Esophagus | ESCC | 1.09e-21 | 4.15e-01 | 0.1122 |
| 79023 | NUP37 | P15T-E | Human | Esophagus | ESCC | 1.83e-16 | 4.01e-01 | 0.1149 |
| 79023 | NUP37 | P16T-E | Human | Esophagus | ESCC | 1.29e-23 | 3.28e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006403110 | Esophagus | ESCC | RNA localization | 166/8552 | 201/18723 | 1.95e-27 | 6.18e-25 | 166 |
| GO:005123617 | Esophagus | ESCC | establishment of RNA localization | 134/8552 | 166/18723 | 1.23e-20 | 1.81e-18 | 134 |
| GO:005102815 | Esophagus | ESCC | mRNA transport | 110/8552 | 130/18723 | 2.76e-20 | 3.80e-18 | 110 |
| GO:005065717 | Esophagus | ESCC | nucleic acid transport | 131/8552 | 163/18723 | 6.94e-20 | 8.46e-18 | 131 |
| GO:005065817 | Esophagus | ESCC | RNA transport | 131/8552 | 163/18723 | 6.94e-20 | 8.46e-18 | 131 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:000640321 | Liver | HCC | RNA localization | 151/7958 | 201/18723 | 3.72e-21 | 5.89e-19 | 151 |
| GO:005123621 | Liver | HCC | establishment of RNA localization | 121/7958 | 166/18723 | 1.61e-15 | 1.19e-13 | 121 |
| GO:005065711 | Liver | HCC | nucleic acid transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
| GO:005065811 | Liver | HCC | RNA transport | 118/7958 | 163/18723 | 8.30e-15 | 5.60e-13 | 118 |
| GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
| GO:005102811 | Liver | HCC | mRNA transport | 97/7958 | 130/18723 | 9.00e-14 | 5.23e-12 | 97 |
| GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
| GO:000640318 | Oral cavity | OSCC | RNA localization | 150/7305 | 201/18723 | 6.90e-25 | 1.98e-22 | 150 |
| GO:00510287 | Oral cavity | OSCC | mRNA transport | 101/7305 | 130/18723 | 2.19e-19 | 3.15e-17 | 101 |
| GO:005065714 | Oral cavity | OSCC | nucleic acid transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
| GO:005065814 | Oral cavity | OSCC | RNA transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
| GO:005123614 | Oral cavity | OSCC | establishment of RNA localization | 121/7305 | 166/18723 | 6.38e-19 | 8.24e-17 | 121 |
| GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa03013 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
| hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa030131 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
| hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
| hsa030136 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
| hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
| hsa0301311 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
| hsa0501429 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
| hsa030132 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
| hsa0501437 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
| hsa030133 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUP37 | SNV | Missense_Mutation | c.184C>G | p.Gln62Glu | p.Q62E | Q8NFH4 | protein_coding | tolerated(1) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUP37 | SNV | Missense_Mutation | c.354N>T | p.Lys118Asn | p.K118N | Q8NFH4 | protein_coding | deleterious(0.02) | possibly_damaging(0.475) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| NUP37 | SNV | Missense_Mutation | c.641C>T | p.Ala214Val | p.A214V | Q8NFH4 | protein_coding | deleterious(0) | possibly_damaging(0.813) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUP37 | SNV | Missense_Mutation | c.499N>T | p.Pro167Ser | p.P167S | Q8NFH4 | protein_coding | deleterious(0.01) | benign(0.262) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| NUP37 | SNV | Missense_Mutation | c.547G>T | p.Val183Phe | p.V183F | Q8NFH4 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NUP37 | SNV | Missense_Mutation | novel | c.497N>T | p.Ser166Phe | p.S166F | Q8NFH4 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NUP37 | SNV | Missense_Mutation | rs144473944 | c.715C>T | p.Arg239Trp | p.R239W | Q8NFH4 | protein_coding | deleterious(0) | possibly_damaging(0.482) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NUP37 | SNV | Missense_Mutation | novel | c.886G>A | p.Val296Ile | p.V296I | Q8NFH4 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUP37 | SNV | Missense_Mutation | novel | c.862C>T | p.Pro288Ser | p.P288S | Q8NFH4 | protein_coding | tolerated(0.31) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUP37 | SNV | Missense_Mutation | novel | c.602T>G | p.Ile201Ser | p.I201S | Q8NFH4 | protein_coding | deleterious(0) | possibly_damaging(0.518) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |